APPENDIX 3 – SCREENING QUESTIONNAIRE



RCR/NCIN CASPAR Project

Centre screening questions

Contact name		Hospital
1.	Are you the MDT Radiology	lead?
	Yes	
	No	(give MDT Lead name)
2.	Are you currently using a pr	oforma for Radiology reporting in this/these cancers?
	Yes (all cancers/Radiologis No Some Radiologists but not a Some cancers but not all Some imaging modalities bu	II
2a. If YES		2b. If NO/not all
How is the proforma used?		Why no proforma?
		 □ No point □ Difficult to implement in RIS □ RIS manufacturer cannot support □ Too time consuming □ Reluctant colleagues □ Other

3. Is integrating a proforma report into your RIS likely to be a problem?		
	Yes	
	No	
	3a. If yes, what is the likely problem?	
	3b. If this problem cannot be overcome, are you willing to use a paper proforma report for the purpose of this pilot? (3 months)	
	□ Yes	
	□ No	
	□ Would need to consult colleagues	
3.	Do you have a means of identifying all newly-diagnosed cases of	
	Lung/prostate/cervical/endometrial/rectal/colon cancers discussed in MDT in the last 3 months?	
	Yes	
	No	
	Not sure(why?)	
4a.	If YES - How would you do this? (& is it the same for all the cancers?)	
	☐ Database search	
	☐ MDT diary/log manual search	
	☐ MDT log + manual search of patient records	
	□ Other	

 identify all newly-diagnosed Lung/prostate/cervical/endometrial/rectal/colon cancer cases from the last 3 months and for the 3 months of the proforma pilot, locate the Radiology reports/proforma reports relating to this cancer, copy them, remove all identifying information from the copy and send to the data management company? Yes No Not sure – would need to consult colleagues If provided with template documentation, would you be able to seek the approval of your organisation's Data Protection Officer (Caldicott Guardian) to share anonymised radiology reports with the case of the proforma pilot,
the RCR and the data management company for data analysis?
the New and the data management company for data analysis:
□ Yes
□ No
□ Possibly - Would need more info about what is involved
6. How many cases of newly-diagnosed Lung/prostate/cervical/endometrial/rectal/colon cancers doe the MDT review for staging per week?
□ Lung
□ Prostate
□ Cervical
□ Endometrial
□ Rectal
□ Colon
7. Do you have a mechanism to formally record cancer staging information at MDT?
□ Yes □ No

4b. Do you have a member/members of the MDT who would have the capacity to:

	you willing to be considered as a lead radiologist in the CASPAR project with responsibility for ng and submitting the requested data from your hospital?
	Yes
	No
	Need more information – offer contact with Gina Brown to discuss participation.
Oncolo	u are selected to participate in the CASPAR project, would you be willing to liaise with the Clinical gy Head of Service in your centre, to ensure there is some feedback from end-user clinicians on a collected through proforma reporting?
	Yes
	No
Not su	re - (why?)
THANK Next st	YOU FOR YOUR TIME teps: The project Steering group will look at all screening information and choose 15 sites to ensure a spread of specialist and generalist departments, those using different RIS systems and with different expected modes of implementing the proformas and to provide similar amounts of data on the 4 proformas. We will be in touch in January to let you know whether your hospital has been chosen for the pilot. Meanwhile please keep February 27 th free for the project launch meeting. If in the meantime a circumstance arises that means you no longer wish to be considered – please let us know on Enquiries@phassociates.com
•	NB After screening - Email thank you for their time to go through screening questionnaire and

provide the next steps info above